Assembly Biosciences Appoints Gina Consylman to Board of Directors
October 20 2020 - 8:00AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, today announced the appointment of Gina Consylman to
its board of directors. Ms. Consylman will also serve as a member
of Assembly’s Audit Committee.
“Gina is an outstanding and complementary addition to Assembly’s
board with extensive senior leadership experience across the full
spectrum of finance, tax, and strategy,” said William Ringo,
chairman of the board at Assembly Biosciences. “From her work at
Ironwood Pharmaceuticals to her many years of experience at global
biotechnology companies like Biogen, we are confident that Gina
will make solid contributions to our success. We are pleased to
welcome her to our board.”
Gina Consylman is a 25-year veteran in the field of accounting,
finance, and tax. Currently, Ms. Consylman is senior vice president
and chief financial officer at Ironwood Pharmaceuticals, a publicly
traded healthcare company, where she leads finance, accounting,
tax, investor relations, communications, and corporate strategy and
development. Ms. Consylman began her career at Ernst & Young
LLP and served in financial leadership roles at a number of
healthcare and technology companies. Ms. Consylman earned a
bachelor’s degree in accounting from Johnson & Wales
University, a master’s degree in taxation from Bentley University,
and is a Certified Public Accountant.
“I am inspired by Assembly Biosciences’ team and its commitment
to the pursuit of life-changing therapeutics,” said Ms. Consylman.
“The company’s achievements to date are indicative of both the
strength of the management team and the foundation of innovative
and promising science. I look forward to providing my insight and
perspectives to help guide their continued advancement in these
important disease areas.”
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage biotechnology company developing
innovative therapeutics targeting hepatitis B virus (HBV) and
diseases associated with the microbiome. The HBV program is focused
on advancing a new class of potent, oral core inhibitors that have
the potential to increase cure rates for chronically infected
patients. The microbiome program is developing novel oral live
microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP manufacturing expertise and
targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology. For more information, visit
assemblybio.com.
Investor ContactAssembly
Biosciences, Inc.Lauren GlaserSenior Vice President, Investor
Relations and Corporate Affairs(415)
521-3828lglaser@assemblybio.com
Media ContactSam Brown Inc.Audra Friis(917)
519-9577ASMBMedia@sambrown.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024